
Opinion|Videos|January 10, 2025
Assessing New Therapies for Retinal Diseases
Panelists discuss how aflibercept 8 mg demonstrates improved durability and maintenance of visual gains compared with 2-mg dosing, potentially reducing treatment burden while maintaining a similar safety profile.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- New Therapies:
- Aflibercept 8 mg
Newsletter
Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Modern Retina
1
Leadership in action during the 2025 AAO named lectures
2
Abeona Therapeutics’ ABO-503 chosen for FDA's Rare Disease Endpoint Advancement Pilot Program
3
AAO 2025: Ashkan Abbey on the outcomes of EYP-1901 for AMD and DME
4
Quantifying Intermittent Retinal Capillary Perfusion in RVO and PDR
5